Balanced news tone
News Sentiment
PPBT sentiment intelligence
Purple Biotech Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
50
Balanced news tone
17 relevant articles
News tone and price action are not far from neutral.
90/100 classification confidence.
directly relevant articles
high-authority source matches
+0.0% over one week, +0.0% over four weeks, trend inactive, and below fair value.
PURPLE BIOTECH LTD-ADR (PPBT) Stock Price & Overview
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
90/100 classification
One-week reaction
0.0%
Price digesting
Trend fit
Trend inactive
0.0% over four weeks
Fair value
-92.6%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
1
Neutral
15
Negative
1
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
ChartMill
Direct company coverage
PURPLE BIOTECH LTD-ADR (PPBT) Stock Price & Overview
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 18:36
- Source
- ChartMill
dars.gov.et
Direct company coverage
Purple Biotech (PPBT) Surges 4.12% as Shares Approach Resistance at $1.86 - Buffered ETF
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- dars.gov.et
Stock Titan
Direct company coverage
Purple Biotech (NASDAQ: PPBT) posts promising IM1240 preclinical data at EACR 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 07:00
- Source
- Stock Titan
TipRanks
Direct company coverage
Purple Biotech Unveils IM1240 Preclinical Data at EACR 2026, Validating CAPTN-3 Immunotherapy Platform
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 07:00
- Source
- TipRanks
dars.gov.et
Direct company coverage
Purple Biotech (PPBT) Slides 3.88% as Stock Hovers Near Support Zone - Pairs Trade
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jun 2026 07:00
- Source
- dars.gov.et
dars.gov.et
Direct company coverage
Purple Biotech Ltd. Q1 2025 Earnings: Losses Continue as Stock Climbs 6.41% - Management Tone Analysis
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 31 May 2026 07:00
- Source
- dars.gov.et
Stock Titan
Direct company coverage
Doctors tied to approved cancer immune therapies join Purple board
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Apr 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
Purple Biotech uses AI to speed antibody drugs for solid tumors
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Mar 2026 07:00
- Source
- Stock Titan
Quiver Quantitative
Direct company coverage
Purple Biotech Ltd. Announces ADS Ratio Change to Regain Nasdaq Compliance Effective March 2, 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Feb 2026 08:00
- Source
- Quiver Quantitative
Barron's
Direct company coverage
This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Feb 2026 08:00
- Source
- Barron's
Stocktwits
Direct company coverage
Purple Biotech Shares Soar 92% On Breakthrough For Experimental Cancer Drug
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Oct 2025 07:00
- Source
- Stocktwits
timothysykes.com
Direct company coverage
Purple Biotech Ltd. Shake-Up: Market Dynamics Unfolding
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Oct 2025 07:00
- Source
- timothysykes.com
Market source
Direct company coverage
Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Sep 2025 07:00
- Source
- Market source
Stocktwits
Direct company coverage
Purple Biotech Stock Hits Nearly 2-Month High On Cancer Drug Trial Success: Retail Thrilled
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Dec 2024 15:27
- Source
- Stocktwits
Zacks Investment Research
Direct company coverage
What is the current Price Target and Forecast for Purple Biotech (PPBT)
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 31 Oct 2022 03:19
- Source
- Zacks Investment Research
Stock Titan
Direct company coverage
Purple Biotech (PPBT) Stock News & Updates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Mar 2021 12:16
- Source
- Stock Titan
MarketBeat
Direct company coverage
Purple Biotech (PPBT) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 31 Dec 2020 13:00
- Source
- MarketBeat